James Rothman

James E.
Rothman is the founder of ARIAD Pharmaceuticals, Inc., founded in 1992.
Dr. Rothman is also the founder of Mojave Therapeutics, Inc. Dr. Rothman currently serves as Senior Advisor & Advisory Board Chairman at Arsenal Capital Management LP, Director at TractManager, Inc., Professor & Director-Nanobiology Institute at Yale School of Medicine, Director at Optimvia LLC, Independent Director at WCG Clinical, Inc. since 2012, and Senior Advisor at Celesta Global Capital Managers LLC.
Former positions include Vice Chairman & Chairman-Cellular Biochemistry at Memorial Sloan Kettering Cancer Center from 1991 to 2004, Director at MDRNA, Inc. from 2008 to 2010, Director at Introgen Therapeutics, Inc. from 2008 to 2009, Professor & Director-Sulzberger Genome at The Trustees of Columbia University in The City of New York from 2004 to 2008, Director at Certara USA, Inc., Director at Adhera Therapeutics, Inc. in 2010, Director at Phenomebio, Inc., Consultant at Genentech, Inc., Advisor at Johnson & Johnson, Consultant at Eli Lilly & Co., Professor at Stanford University from 1978 to 1988, Advisor at GE Healthcare Ltd. (United Kingdom), Professor at Princeton University from 1988 to 1991, Chief Scientist at General Electric Healthcare Technologies, Inc. from 2002 to 2006, Consultant at GlaxoSmithKline (New Jersey), and Strategic Advisor at The Courtagen Group LLC.
Education includes a doctorate from Harvard University and an undergraduate degree from Yale University.